{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"34","value":"14.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Number of non-ICU inpatient days.","dispersionType":"Full Range","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one infusion of JCAR017 who were monitored inpatient","reportingStatus":"POSTED","timeFrame":"From first dose after JCAR017 infusion to up to approximately 24 months","title":"Numbers of Non-intensive Care Unit (ICU) Inpatient Days","type":"SECONDARY","unitOfMeasure":"Day"}